{
  "data_version": "seed-0.6 · 2026-08-29",
  "source": "https://finance.foundation",
  "license": "CC BY 4.0",
  "entity": "company",
  "data": {
    "id": "csl",
    "name": "CSL",
    "legal_name": "CSL Limited",
    "ticker": "CSL",
    "exchange": "asx",
    "country": "australia",
    "sector": "Healthcare",
    "industry": "Plasma therapies & vaccines",
    "market_cap_usd_bn": 65,
    "currency": "AUD",
    "website": "https://www.csl.com",
    "founded": 1916,
    "description": "Australian biotech and one of the world's largest makers of plasma-derived therapies (CSL Behring), also active in influenza vaccines (Seqirus) and iron-deficiency and nephrology treatments (Vifor).",
    "identifiers": {
      "lei": "529900ECSECK5ZDQTE14",
      "isin": "AU000000CSL8",
      "figi": "BBG001S7YNK1"
    }
  },
  "links": {
    "html": "https://finance.foundation/companies/csl",
    "graph": "https://finance.foundation/api/v1/graph/companies/csl"
  }
}